In tumor cells, interferon gamma (IFN-g-), which responds to an antitumor immune activity, is a major regulator of PD-L1; PD-L1 expression in tumors can also be activated by oncogenic mutations, such as the deletion of phosphatase and tensin homologue in gliomas (38–40). The gene discussed is IFNG; the disease is glioma.